MedTrace Logo

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

NCT03864068 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2026-01-07

No results posted yet for this study

Summary

To determine if Inositol, a dietary supplement, will improve ovarian and adrenal androgen excess in women with Polycystic Ovarian Syndrome(PCOS).

Conditions

  • Polycystic Ovary Syndrome
  • Anovulation
  • Hyperandrogenism
  • Insulin Resistance
  • Glucose Intolerance
  • Metabolic Complication

Interventions

OTHER

Placebo

Placebo

DRUG

Inositol

1gm/bid, 2gm/bid or 3gm/bid of Inositol powder

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • Richard S. Legro, M.D. · Penn State College of Medicine, Hershey Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-24
Primary Completion
2025-12-10
Completion
2025-12-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03864068 on ClinicalTrials.gov